FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.837,88 +62,50 (+0,17%) Nasdaq
15.313,97 -287,53 (-1,84%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
82,90 +0,17 (+0,21%) Bitcoin EUR
59.884,88 +7,77 (+0,01%)
Lantheus Holdings, Inc. (LNTH)
| Chiusura precedente | 62,33 |
| Aperto | 62,10 |
| Denaro | 63,08 x 200 |
| Lettera | 63,18 x 100 |
| Min-Max giorno | 61,47 - 63,91 |
| Intervallo di 52 settimane | 50,20 - 100,85 |
| Volume | |
| Media Volume | 998.580 |
| Capitalizzazione | 4,328B |
| Beta (5 anni mensile) | 0,54 |
| Rapporto PE (ttm) | 13,58 |
| EPS (ttm) | 4,65 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 97,50 |
GlobeNewswireLantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held September 9-13, 2023 in Vienna, Austria. PYLARIFY AI™ (aPROMI
- GlobeNewswire
Lantheus to Present at the Wells Fargo Healthcare Conference
BEDFORD, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, September 7. To access a li
- GlobeNewswire
Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
Agreement enhances Lantheus’ strong liquidity position and supports continued pipeline advancement and commercial readinessBEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the divestiture of its RELISTOR (methylnaltrexone bromid
